Novo Nordisk AS Class B NOV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
GLP-1 drugs could ease back and knee pain, but doctors say there are risks for older adults
-
Novo Nordisk Says FDA Review of Hemophilia Drug Is Hitting Delays
-
Eli Lilly Says Zepbound Delivers Greater Weight Loss Than Higher-Dose Version of Novo's Wegovy
-
Taking Ozempic and worried about vision loss? This test can help you understand your risk.
-
Novo Nordisk strikes second licensing deal since frosty capital-markets day
-
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma
-
After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company's stock soaring
-
Novo Nordisk to Pay Up to $1.3 Billion for Nanexa's Drug Delivery Technology
Trading Information
- Previous Close Price
- €34.28
- Day Range
- €34.22–34.61
- 52-Week Range
- €30.42–—
- Bid/Ask
- €34.49 / €34.50
- Shares Outstanding
- 4.41B
- Market Cap
- €152.72B
- Volume/Avg
- — / 173,306
Key Statistics
- Price/Earnings (Normalized)
- 8.87
- Price/Sales
- 3.46
- Dividend Yield (Trailing)
- 4.57%
- Dividend Yield (Forward)
- 4.57%
- Dividend Payment Schedule
- Mar, Aug
- Total Yield
- 5.09%
Company Profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 68,794
- Website
- https://www.novonordisk.com
Competitors
Valuation
|
Metric
|
NOV
|
SNY
|
AZN
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.87 | 11.24 | 15.16 |
Price/Book Value | 5.12 | 1.31 | 5.07 |
Price/Sales | 3.46 | 1.68 | 4.24 |
Price/Cash Flow | 8.28 | 6.95 | 16.77 |
Price/Earnings
NOV
SNY
AZN
Financial Strength
|
Metric
|
NOV
|
SNY
|
AZN
|
|---|---|---|---|
Quick Ratio | 0.64 | 0.49 | 0.66 |
Current Ratio | 0.87 | 0.99 | 0.89 |
Interest Coverage | — | 8.05 | 7.99 |
Quick Ratio
NOV
SNY
AZN
Profitability
|
Metric
|
NOV
|
SNY
|
AZN
|
|---|---|---|---|
Return on Assets (Normalized) | 21.31% | 7.96% | 9.00% |
Return on Equity (Normalized) | 59.99% | 14.96% | 21.69% |
Return on Invested Capital (Normalized) | 34.79% | 11.28% | 14.36% |
Return on Assets
NOV
SNY
AZN
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|^CQPjCH | LOCK|m^ | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|xVp>%^ | LOCK|>m | $612B | |||
| AbbVie Inc
ABBV
| LOCK|QC>Vql | LOCK|N! | $500B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|&fj>SK& | LOCK|M$ | $368B | |||
| Merck & Co Inc
MRK
| LOCK|tL!$%Xm | LOCK|TK@ | $354B | |||
| Novartis AG ADR
NVS
| LOCK|zy&ftv^! | LOCK|M>$ | $287B | |||
| AstraZeneca PLC
AZN
| LOCK|>^c>Dk>% | LOCK|^^ | $256B | |||
| Amgen Inc
AMGN
| LOCK|S?&K!%LT | LOCK|?#t | $230B | |||
| Gilead Sciences Inc
GILD
| LOCK|@%dj<c? | LOCK|q% | $190B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Y!Rlj@N | LOCK|TQ$ | $170B |
United States